Breast Cancer Research and Treatment

, Volume 107, Issue 1, pp 119–122 | Cite as

BARD1 and breast cancer in Poland

  • Anna Jakubowska
  • Cezary Cybulski
  • Anna Szymańska
  • Tomasz Huzarski
  • Tomasz Byrski
  • Jacek Gronwald
  • Tadeusz Dębniak
  • Bohdan Górski
  • Elżbieta Kowalska
  • Steven A. Narod
  • Jan Lubiński
Epidemiology

Abstract

Purpose

To investigate whether or not a genetic variant in BARD1 (Cys557Ser) contributes to early-onset breast cancer in Poland, or modifies the risk of breast cancer in women with an inherited predisposition to breast cancer.

Experimental design

We studied 3,188 unselected Polish women with breast cancer and 1,038 healthy controls. All women were genotyped for the BARD1 Cys557Ser variant and for known founder mutations in BRCA1 (three mutations), CHEK2 (four mutations), and NBS1 (one mutation).

Results

A BARD1 variant was seen in 150 of 3,188 breast cancer cases (4.7%) and in 40 of 1,038 controls (3.8%) (OR = 1.2; 95% CI = 0.9–1.7). The risk associated with the BARD1 variant was not significantly greater in women with familial cancer (OR = 1.5; 95% CI = 0.8–2.7), or with an inherited mutation in BRCA1 (OR = 0.9; 95% CI = 0.4–2.2), CHEK2 (OR = 1.0; 95% CI = 0.5–2.1), or NBS1 (OR = 1.3; 95% CI = 0.2–10.2). Modest associations were observed among the subgroups of women with very early onset breast cancer (OR = 2.9; 95% CI = 1.2–7.1) and with medullary breast cancer (OR = 1.8; 95% CI = 0.9–3.7).

Conclusion

There was no clear association between the presence of the BARD1 Cys557Ser allele and breast cancer in Poland. Furthermore, the BARD1 Cys557Ser allele does not appear to modify the risk of breast cancers among carriers of BRCA1 mutations, or of other predisposing mutations. The allele may predispose to breast cancers of certain histologic subtypes, but further studies are needed to confirm these findings.

Keywords

BARD1 BRCA1 Breast cancer CHEK2 NBS1 

References

  1. 1.
    Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRefGoogle Scholar
  2. 2.
    Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792PubMedCrossRefGoogle Scholar
  3. 3.
    CHEK2 Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55–59CrossRefGoogle Scholar
  4. 4.
    Cybulski C, Górski B, Huzarski T, Masojc B, Mierzejewski M, Dębniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymańska A, Szymańska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubiński J (2004) CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131–1135PubMedCrossRefGoogle Scholar
  5. 5.
    Swift M, Reitnauer PJ, Morrell D, Chase CL (1987) Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 316:1289–1294PubMedCrossRefGoogle Scholar
  6. 6.
    Górski B, Dębniak T, Masojc B, Mierzejewski M, Medrek K, Cybulski C, Jakubowska A, Kurzawski G, Chosia M, Scott R, Lubiński J (2003) Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 106:379–381PubMedCrossRefGoogle Scholar
  7. 7.
    Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R (1996) Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430–440PubMedCrossRefGoogle Scholar
  8. 8.
    Stacey SN, Sulem P, Johannsson OT, Helgason A, Gudmundsson J, Kostic JP, Kristjansson K, Jonsdottir T, Sigurdsson H, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Bergthorsson JT, Amundadottir LT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K (2006) The BARD1 Cys557Ser variant and breast cancer risk in Iceland. PLoS Med 3:e217PubMedCrossRefGoogle Scholar
  9. 9.
    Karppinen SM, Barkardottir RB, Backenhorn K, Sydenham T, Syrjakoski K, Schleutker J, Ikonen T, Pylkas K, Rapakko K, Erkko H, Johannesdottir G, Gerdes AM, Thomassen M, Agnarsson BA, Grip M, Kallioniemi A, Kere J, Aaltonen LA, Arason A, Moller P, Kruse TA, Borg A, Winqvist R (2006) Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies. J Med Genet 43:856–862PubMedCrossRefGoogle Scholar
  10. 10.
    Lubiński J, Górski B, Huzarski T, Byrski T, Gronwald J, Serrano-Fernandez P, Domagala W, Chosia M, Ucinski M, Grzybowska E, Lange D, Maka B, Mackiewicz A, Karczewska A, Breborowicz J, Lamperska K, Stawicka M, Gozdecka-Grodecka S, Bebenek M, Sorokin D, Wojnar A, Haus O, Sir J, Mierzwa T, Niepsuj S, Gugala K, Gozdz S, Sygut J, Kozak-Klonowska B, Musiatowicz B, Posmyk M, Kordek R, Morawiec M, Zambrano O, Wasko B, Fudali L, Skret J, Surdyka D, Urbanski K, Mitus J, Rys J, Szwiec M, Rozmiarek A, Dziuba I, Wandzel P, Wisniowski R, Szczylik C, Kozak A, Kozlowski W, Narod SA (2006) BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99:71–76PubMedCrossRefGoogle Scholar
  11. 11.
    Lahiri DK, Schnabel B (1993) DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet 31:321–328PubMedCrossRefGoogle Scholar
  12. 12.
    Górski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, Mackiewicz A, Stawicka M, Bebenek M, Sorokin D, Fiszer-Maliszewska L, Haus O, Janiszewska H, Niepsuj S, Gozdz S, Zaremba L, Posmyk M, Pluzanska M, Kilar E, Czudowska D, Wasko B, Miturski R, Kowalczyk JR, Urbanski K, Szwiec M, Koc J, Dębniak B, Rozmiarek A, Dębniak T, Cybulski C, Kowalska E, Toloczko-Grabarek A, Zajaczek S, Menkiszak J, Medrek K, Masojc B, Mierzejewski M, Narod SA, Lubiński J (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686PubMedCrossRefGoogle Scholar
  13. 13.
    Górski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, Stawicka M, Gozdecka-Grodecka S, Szwiec M, Urbanski K, Mitus J, Marczyk E, Dziuba J, Wandzel P, Surdyka D, Haus O, Janiszewska H, Dębniak T, Toloczko-Grabarek A, Medrek K, Masojc B, Mierzejewski M, Kowalska E, Narod SA, Lubiński J (2005) Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92:19–24PubMedCrossRefGoogle Scholar
  14. 14.
    Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Dębniak T, Wokolorczyk D, Jakubowska A, Kowalska E, Oszurek O, Narod SA, Lubiński J (2006) CHEK2-positive breast cancers in young Polish women. Clin Cancer Res 12:4832–4835PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Anna Jakubowska
    • 1
  • Cezary Cybulski
    • 1
  • Anna Szymańska
    • 1
  • Tomasz Huzarski
    • 1
  • Tomasz Byrski
    • 1
  • Jacek Gronwald
    • 1
  • Tadeusz Dębniak
    • 1
  • Bohdan Górski
    • 1
  • Elżbieta Kowalska
    • 1
  • Steven A. Narod
    • 2
  • Jan Lubiński
    • 1
  1. 1.International Hereditary Cancer Center, Department of Genetics and PathologyPomeranian Medical UniversitySzczecinPoland
  2. 2.Centre for Research on Women’s HealthTorontoCanada

Personalised recommendations